
    
      Investigators will evaluate in a single ascending dose (SAD) and multiple ascending dose
      (MAD) fashion, the safety, pharmacokinetics and effect on target biomarkers of coagulation,
      cell adhesion, and leukocyte and platelet activation of GMI-1271, an E-selectin antagonist,
      in healthy volunteers.
    
  